Dicerna Pharmaceuticals Inc (DRNA)

Common Stock

38.22  +0.22 (+0.58%)

After market: 38.24 +0.02 (+0.05%)

Fundamental Rating

2

Taking everything into account, DRNA scores 2 out of 10 in our fundamental rating. DRNA was compared to 587 industry peers in the Biotechnology industry. The financial health of DRNA is average, but there are quite some concerns on its profitability. DRNA is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

DRNA had negative earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -16.12%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Operating Margin and Gross Margin are not available for DRNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) -64.53%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for DRNA has been increased compared to 1 year ago.
DRNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of 1.63, we must say that DRNA is in the distress zone and has some risk of bankruptcy.
DRNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.63
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 2.46 indicates that DRNA has no problem at all paying its short term obligations.
A Quick Ratio of 2.46 indicates that DRNA has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 2.46
Quick Ratio 2.46

More info and screens

4

3. Growth

3.1 Past

The earnings per share for DRNA have decreased by -1.24% in the last year.
Looking at the last year, DRNA shows a very strong growth in Revenue. The Revenue has grown by 47.85%.
DRNA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 282.76% yearly.
EPS 1Y (TTM)-1.24%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q24.14%
Revenue 1Y (TTM)47.85%
Revenue growth 3Y447.7%
Revenue growth 5Y282.76%
Revenue growth Q2Q28.79%

3.2 Future

The Earnings Per Share is expected to grow by 0.58% on average over the next years.
DRNA is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -2.70% yearly.
EPS Next Y-13.03%
EPS Next 2Y-15.97%
EPS Next 3Y-20.83%
EPS Next 5Y0.58%
Revenue Next Year-6.12%
Revenue Next 2Y2.93%
Revenue Next 3Y-3.27%
Revenue Next 5Y-2.7%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DRNA. In the last year negative earnings were reported.
Also next year DRNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -20.61

4.3 Compensation for Growth

A cheap valuation may be justified as DRNA's earnings are expected to decrease with -20.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.97%
EPS Next 3Y-20.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DRNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Dicerna Pharmaceuticals Inc

NASDAQ:DRNA (12/27/2021, 7:42:47 PM)

After market: 38.24 +0.02 (+0.05%)

38.22

+0.22 (+0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.97B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.12%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) -64.53%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.46
Quick Ratio 2.46
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-1.24%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-13.03%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)47.85%
Revenue growth 3Y447.7%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y